S1755 Lipid Lowering Therapies and Primary Sclerosing Cholangitis: A Mendelian Randomization Study

Manish Paranjpe
DOI: https://doi.org/10.14309/01.ajg.0001036388.34898.d6
2024-10-26
The American Journal of Gastroenterology
Abstract:Observational studies have implicated statin use with decreased risk of developing primary sclerosing cholangitis, among other chronic liver diseases. Residual confounding and reverse causality bias limits the interpretability of these observational studies. Whether there is causal association between lipid-lowering therapies and the development of Primary sclerosing cholangitis (PSC) is unknown. The present study sought to investigate whether Low-density lipoprotein cholesterol (LDL-C) lowering therapy is causally associated with a decreased risk of PSC. We further investigated whether potential associations are driven by β-Hydroxy β-methylglutaryl-CoA (HMG-CoA) reductase-independent or HMG-CoA dependent mechanisms.
gastroenterology & hepatology
What problem does this paper attempt to address?